PRESS RELEASE

« Back

Retrophin to Report Fourth Quarter and Full Year 2015 Financial Results

Feb 11, 2016

SAN DIEGO, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Conference Call Information

Date:Thursday, February 25, 2016   
Time:4:30 p.m. ET 
Dial-in numbers:+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) 
Confirmation code:49757304 
Live webcast:www.retrophin.com in the "Events & Presentations" section of the "Investors" page


A replay of the call will be available 7:30 p.m. ET, February 25, 2016 to 11:59 p.m. ET, March 3, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 49757304.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the company's marketed products, Chenodal®, Cholbam® and Thiola®.

Retrophin.com

Contact:

Chris Cline, CFA

Director, Investor Relations

646-564-3680

IR@retrophin.com 

Primary Logo

Source: Retrophin, Inc.

News Provided by Acquire Media